<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00258128</url>
  </required_header>
  <id_info>
    <org_study_id>CHS 00-01</org_study_id>
    <secondary_id>R37DK051729</secondary_id>
    <secondary_id>R01DK051729</secondary_id>
    <nct_id>NCT00258128</nct_id>
  </id_info>
  <brief_title>Effect of Salicylate on Glucose Metabolism in Insulin Resistance States</brief_title>
  <official_title>Effect of Salicylate on Glucose Metabolism in Insulin Resistance States</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joslin Diabetes Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Joslin Diabetes Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data supports diet induced obesity leads to activation of the IKK/NF-kB inflamatory pathway
      and that chronic inflammation leads to insulin resistance and diabetes. In rodents,
      salicylates inhibit IKK/NF-kB and may improve insulin sensitivity. We will study if this is
      true in people.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Please see the following review articles on this topic:

      Shoelson SE, Lee J, Goldfine AB. (2006) Inflammation in insulin resistance. J. Clin. Invest.
      116, 1793-1801.

      Goldfine AB, Fonseca V and Shoelson SE (2010) Therapeutic approaches to target inflammation
      in type 2 diabetes. Clin Chem. 57, 162-167.

      Donath MY and Shoelson SE (2011) Type 2 diabetes as an inflammatory disease. Nat Rev Immunol.
      11, 98-107.

      Goldfine AB and Shoelson SE (2017) Therapeutic approaches targeting inflammation for diabetes
      and associated cardiovascular risk. J Clin Invest. 127, 83-93.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Glucose</measure>
    <time_frame>4 weeks</time_frame>
    <description>fasting glucose</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adiponectin</measure>
    <time_frame>4 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">17</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the salsalate 4.0 g/d arm.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>This third small study has a randomized, masked, placebo controlled parallel design to compare salsalate 4.0 g/d to placebo. This is the placebo arm.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Salsalate</intervention_name>
    <description>Active</description>
    <arm_group_label>Treatment</arm_group_label>
    <other_name>Disalcid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo for salslate, used only in the third trial</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        age 18 to 65 years, inclusive; HbA1c &gt;6.0% (off medication-diabetic) normal hemoglobin and
        hematocrit, without donation of blood in the previous 2 months; without involvement in any
        study evaluating an investigational drug or device for the previous 2 months; normal
        clotting studies; female postmenopausal or surgically sterile, or using barrier or oral
        contraception and with a negative pregnancy test.

        Exclusion Criteria:

        pregnant or lactating women; patients with persistent ketonuria or a history of
        ketoacidosis (suggesting the need for insulin therapy); current of previous use of insulin
        for glucose control; patients with abnormal liver function defined as elevation of
        bilirubin, alkaline phosphatase, ALT, AST, or GGTP more than 1.5 times the upper limit of
        normal; patients with kidney disease (serum creatinine &gt; 1.5 mg/dL) macroalbuminuria (1+
        protein on a standard urine dip-stick, or &gt; 300 mg urinary albumin/day)- (patients with
        microalbuminuria will be enrolled); patients with any significant diseases or conditions,
        including emotional or psychiatric disorders and substance abuse, including history of
        binge drinking, that, in the opinion of the investigator, are likely to alter the patient's
        ability to complete the study; patients with metabolic acidosis (abnormal anion gap);
        history of gastric ulcer, dyspepsia, or upper or lower GI bleed; history of allergy to
        aspirin, or bleeding diathesis or currently on oral anticoagulants including warfarin,
        heparin, aspirin or other NSAIDs; patients with major vascular event within 6 months of
        screening for the study (e.g., myocardial infarction stroke, coronary artery bypass graft
        (CABG) surgery, angioplasty, peripheral vascular surgery); patients with chronic heart
        disease, or a history of myocardial infarction or stroke. Symptomatic angina pectoris or
        cardiac insufficiency as defined by the NYHA; classification as Functional Class III or IV;
        patients with HbA1C &gt; 13% (normal range 4-6%); patients who smoke more than one pack of
        cigarettes daily; patients taking treatment medications known to affect insulin sensitivity
        (e.g. diuretics, beta-blockers); patients taking warfarin, heparin or NSAID on a chronic
        basis; patients with inadequately controlled serum lipid levels (total cholesterol ≥ 275
        mg/dL and fasting triglycerides ≥ 450 mg/dL); patients with history of cancer within 5
        years prior to screening for the study other than basal cell carcinoma; active alcohol or
        other substance abuse.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Steven Shoelson</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joslin Diabetes Center</affiliation>
  </overall_official>
  <reference>
    <citation>Fleischman A, Shoelson SE, Bernier R, Goldfine AB. Salsalate improves glycemia and inflammatory parameters in obese young adults. Diabetes Care. 2008 Feb;31(2):289-94. Epub 2007 Oct 24.</citation>
    <PMID>17959861</PMID>
  </reference>
  <reference>
    <citation>Shoelson SE, Lee J, Goldfine AB. Inflammation and insulin resistance. J Clin Invest. 2006 Jul;116(7):1793-801. Review. Erratum in: J Clin Invest. 2006 Aug;116(8):2308.</citation>
    <PMID>16823477</PMID>
  </reference>
  <results_reference>
    <citation>Goldfine AB, Silver R, Aldhahi W, Cai D, Tatro E, Lee J, Shoelson SE. Use of salsalate to target inflammation in the treatment of insulin resistance and type 2 diabetes. Clin Transl Sci. 2008 May;1(1):36-43. doi: 10.1111/j.1752-8062.2008.00026.x.</citation>
    <PMID>19337387</PMID>
  </results_reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>November 22, 2005</study_first_submitted>
  <study_first_submitted_qc>November 22, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 24, 2005</study_first_posted>
  <results_first_submitted>December 17, 2012</results_first_submitted>
  <results_first_submitted_qc>April 8, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">April 30, 2019</results_first_posted>
  <last_update_submitted>April 8, 2019</last_update_submitted>
  <last_update_submitted_qc>April 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Salicylsalicylic acid</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This study was active between 2000-2008. The location was an accademic clinic setting in the USA.</recruitment_details>
      <pre_assignment_details>Subjects were instructed to monitor fasting blood glucose levels and with symptoms of hyperglycemia or hypoglycemia, and to avoid changing dietary or exercise habits.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Salsalate 4.0 g/d</title>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This trial planned 8-9 participants per arm.</population>
      <group_list>
        <group group_id="B1">
          <title>Salsalate</title>
          <description>Randomized cohorts - Active</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Randomized cohorts - Placebo</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="17"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51" spread="12"/>
                    <measurement group_id="B2" value="54" spread="8"/>
                    <measurement group_id="B3" value="52" spread="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Glucose</title>
        <description>fasting glucose</description>
        <time_frame>4 weeks</time_frame>
        <population>Receiving one dose of study drug and with measured value</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Fasting glucose</description>
          </group>
          <group group_id="O2">
            <title>Salsalate</title>
            <description>Fasting glucose</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose</title>
          <description>fasting glucose</description>
          <population>Receiving one dose of study drug and with measured value</population>
          <units>mmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.1" spread="0.3"/>
                    <measurement group_id="O2" value="6.4" spread="0.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Adiponectin</title>
        <time_frame>4 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Salsalate</title>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
          </group>
        </group_list>
        <measure>
          <title>Adiponectin</title>
          <units>mg/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.7" spread="2.5"/>
                    <measurement group_id="O2" value="10.6" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>one month</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Salsalate</title>
          <description>Active Drug</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo - for salsalate</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="8"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Small study size, sort duration of treatment, multiple endpoints.
See manuscript:
Goldfine AB, et al. Clin Transl Sci. 2008 May;1(1):36-43.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Allison B. Goldfine, MD</name_or_title>
      <organization>Joslin Diabetes Center</organization>
      <phone>617-309-2400</phone>
      <email>allison.goldfine@joslin.harvard.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

